How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

699 results for

Cardiovascular rehabilitation

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

601. Unstable angina and NSTEMI: early management

) cardiac rehabilitation (in line with 'MI – secondary prevention' , NICE clinical guideline 172) management of cardiovascular risk factors and drug therapy for secondary prevention (in line with 'MI – secondary prevention' , NICE clinical guideline 172, and 'Lipid modification' , NICE clinical guideline 67) lifestyle changes (in line with 'MI – secondary prevention' , NICE clinical guideline 172). Unstable angina and NSTEMI: early management (CG94) © NICE 2018. All rights reserved. Subject to Notice (...) with 'MI – secondary prevention' , NICE clinical guideline 172) cardiac rehabilitation (in line with 'MI – secondary prevention' , NICE clinical guideline 172) management of cardiovascular risk factors and drug therapy for secondary prevention (in line with 'MI – secondary prevention' , NICE clinical guideline 172, and 'Lipid modification' , NICE clinical guideline 67) lifestyle changes (in line with 'MI – secondary prevention' , NICE clinical guideline 172). 1.5.11 Make cardiac rehabilitation equally

2010 National Institute for Health and Clinical Excellence - Clinical Guidelines

602. SNAP: a population health guide to behavioural risk factors in general practice

Overweight and obesity 35 5.1.3 Nutrition 36 5.1.4 Alcohol 36 5.1.5 Physical activity 36 5.2 Patient education, nonpharmacological scripts 37 5.3 Specific organisations 37 5.4 Estimation of cardiovascular risk 37 5.5 Short training courses 38 6. References 40 Appendix 1 Grading of evidence and recommendations Appendix 2 Example SNAP care plan Appendix 3 Example Practice SNAP inventory Appendix 4 Estimation of cardiovascular riskA population health guide to behavioural risk factors in general practice 3 1 (...) Diets low in fruit and vegetables have been causally linked to cancer and cardiovascular disease (CVD), accounting for nearly 3% of the total burden of disease (men 3%, women 2.4%). 8 The most recent national data on the prevalence of overweight and obesity in Australian children and adolescents reports that between 20–25% of Australian children and adolescents are either overweight or obese. 9 1.3 Alcohol Light or moderate alcohol consumption reduces the total burden of disease by 2.8%. Excessive

2014 The Royal Australian College of General Practitioners

603. AAWC Pressure Ulcer Guidelines

2007) or severe chronic or terminal disease (Fowler et al.2008) b. Diabetes, with Hb A1c > 6.5 to document blood glucose control (Fowler et al.2008; Amer. Diabetes Assn. 2009) c. Cardiovascular disease or condition including cardiovascular accident (CVA) leading to altered sensation or ability to move (Fowler et al.2008; De Laat et al 2007; IHI 2007) d. Gastrointestinal, genitourinary, renal, endocrine or pulmonary disease or condition (IHI 2007) e. Peripheral vascular disease/condition: assess (...) to maintain adequate nutrition and enteral nutrition is not an option and if consistent with patient and family wishes (Compton, 2008) d. Offer hydrating fluids with repositioning schedule. Offer additional fluids if medically appropriate and patient has dehydration, fever, diaphoresis, diarrhea or heavily draining wounds. Document fluid intake in patients unable to hydrate themselves (RNAO) C. REHABILITATIVE AND RESTORATIVE PROGRAMS 1. Address immobility and/or inactivity in bed- or chair-bound patients

2011 Association for the Advancement of Wound Care

604. Guidelines for the management of dyslipidaemias

Guidelines for the management of dyslipidaemias ESC/EAS GUIDELINES ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Developed with the special contribution of: European Association for Cardiovascular Prevention & Rehabilitation † Authors/Task Force Members: Z ? eljko Reiner * (ESC Chairperson) (Croatia) Alberico L. Catapano * (EAS Chairperson (...) , Italy. Tel: +39 02 5031 8302, Fax:+39 02 5031 8386, Email: Alberico.Catapano@unimi.it † Other ESC entities having participated in the development of this document: Associations: Heart Failure Association. Working Groups: Cardiovascular Pharmacology and Drug Therapy, Hypertension and the Heart, Thrombosis. Councils: Cardiology Practice, Primary Cardiovascular Care, Cardiovascular Imaging. The content of these European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS

2011 European Society of Cardiology

605. Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation

Cardiovascular Interventions, European Association for Cardiovascular Prevention & Rehabilitation. Working Groups: Working Group on Cardiovascular Pharmacology and Drug Therapy, Working Group on Thrombosis, Working Group on Cardiovascular Surgery, Working Group on Acute Cardiac Care, Working Group on Atherosclerosis and Vascular Biology, Working Group on Coronary Pathophysiology and Microcirculation. Councils: Council on Cardiovascular Imaging, Council for Cardiology Practice. The content of these European (...) activated clotting time ACUITY Acute Catheterization and Urgent Intervention Triage strategY AF atrial ?brillation AHA American Heart Association APPRAISE Apixaban for Prevention of Acute Ischemic Events aPTT activated partial thromboplastin time ARB angiotensin receptor blocker ARC Academic Research Consortium ATLAS Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Aspirin With or Without Thienopyridine Therapy in Subjects with Acute Coronary Syndrome BARI-2D Bypass Angioplasty

2011 European Society of Cardiology

606. Diagnosis and Treatment of Peripheral Artery Diseases

. Victor Aboyans, Department of Cardiology, Dupuytren University Hospital, 2 Martin Luther King ave., Limoges 87042, France. Tel:+33 555 056 310, Fax:+33 555 056 384, Email: vaboyans@ucsd.edu. ESC entities having participated in the development of this document: Associations: European Association for Cardiovascular Prevention and Rehabilitation (EACPR), European Association of Percutaneous Cardiovascular Interventions (EAPCI), Heart Failure Association (HFA). Working Groups: Atherosclerosis (...) and Vascular Biology, Thrombosis, Hypertension and the Heart, Peripheral Circulation, Cardiovascular Pharmacology and Drug Therapy, Acute Cardiac Care, Cardiovascular Surgery. Councils: Cardiology Practice, Cardiovascular Imaging, Cardiovascular Nursing and Allied Professions, Cardiovascular Primary Care. The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may

2011 European Society of Cardiology

607. 2011 Update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia Full Text available with Trip Pro

Stewart 3 Andrew Sindone 4 John J Atherton 5 1 Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC. 2 Department of Cardiology, St Vincent’s Hospital, Melbourne, VIC. 3 Department of Preventative Cardiology, Baker IDI Heart and Diabetes Institute, Melbourne, VIC. 4 Heart Failure Unit and Department of Cardiac Rehabilitation, Concord Hospital, Sydney, NSW. 5 Department of Cardiology, Royal Brisbane (...) Natriuretic peptides The 2006 guidelines reported that titration of drug therapy according to plasma levels of N-terminal pro B-type natriuretic peptide (proBNP) had been associated with reduced cardiovascular events in a small study. Large RCTs have evaluated this strategy (using plasma levels of either BNP or N-terminal proBNP) compared with standard therapy for patients with CHF. - Recent meta-analyses reported a significant reduction in all-cause mortality for patients with CHF and low ejection

2011 MJA Clinical Guidelines

608. Consensus-Based Clinical Practice Guideline for the Management of Volatile Substance Use in Australia

Recommendations 87 9.3 Summary of evidence and expert opinion 89 10. Psychological therapies 91 10.1 Psychological therapies for VSu 91 10.2 Recommendations 92 10.3 Summary of evidence and expert opinion 99 11. Activity and youth development programs 101 11.1 Activity and youth development programs as therapy for VSu 101 11.2 Recommendations 104 11.3 Summary of evidence and expert opinion 106 12. Residential rehabilitation 109 12.1 Residential rehabilitation for substance use 109 12.2 Outstation (...) rehabilitation for VSu 110 12.3 Recommendations 112 12.3 Summary of evidence and expert opinion 114 13. Managing co-existing health conditions 117 13.1 Comorbidity in people who use volatile substances 117 13.2 Recommendations 119 13.3 Summary of evidence and expert opinion 120 14. Aftercare 121 14.1 Aftercare in VSu management 121 14.2 Recommendations 122 14.3 Summary of evidence and expert opinion 123 15. Future research 125 15.1 VSu research 125 15.2 Recommendations 125 16. Clinical questions 127 Useful

2011 National Health and Medical Research Council

609. Guidance on competencies for spinal cord stimulation

Guidance on competencies for spinal cord stimulation Contents Introduction A: Core competencies for practitioners in Pain Medicine Appendix A: Curriculum B: Competencies for practitioners in Pain Medicine who are providers in an SCS service Appendix B: Curriculum Guidance on competencies for Spinal Cord Stimulation Page 2 4 5 6 8 Endorsed by: Introduction Spinal cord stimulation (SCS) has been used for more than 40 years for a variety of conditions including pain and cardiovascular problems (...) . in children 3. Patient selection, screening and preparation for therapy a. physical b. psychological c. social aspects d. balanced assessment of benefits/risks e. comprehensive understanding of alternatives to SCS therapy f. management of patient expectations g. provision of rehabilitative support following SCS insertion 4. Interactions of SCS systems with a. medical/electrical/magnetic equipment e.g. diathermy, physiotherapy equipment b. MRI scanners c. other implanted devices e.g. cardiac pacemakers 5

2011 Royal College of Anaesthetists

610. Temporomandibular disorders (TMDs)

for local implementation QIPP - Options for local implementation Nonsteroidal anti-inflammatory drugs (NSAIDs) Review the appropriateness of NSAID prescribing widely and on a routine basis, especially in people who are at higher risk of both gastrointestinal (GI) and cardiovascular (CV) morbidity and mortality (for example, older people). If an NSAID is needed, use ibuprofen (1200 mg per day or less) or naproxen (1000 mg per day or less). Use the lowest effective dose and the shortest duration

2016 NICE Clinical Knowledge Summaries

611. Olecranon bursitis

in people who are at higher risk of both gastrointestinal (GI) and cardiovascular (CV) morbidity and mortality (e.g. older patients). If initiating an NSAID is obligatory, use ibuprofen (1200 mg per day or less) or naproxen (1000 mg per day or less). Use the lowest effective dose and the shortest duration of treatment necessary to control symptoms. Review patients currently prescribed NSAIDs. If continued use is necessary, consider changing to ibuprofen (1200 mg per day or less) or naproxen (1000 mg per

2016 NICE Clinical Knowledge Summaries

612. Macular degeneration - age-related

with conflicting evidence as to their effects, and if they do increase the risk, the risk is small. These include: Hypertension. There is no evidence that treatments to lower blood pressure can prevent the development or progression of the disease. Cardiovascular disease. Evidence is conflicting as to whether statins have a role in preventing or delaying the onset or progression of AMD. Regular aspirin use. A consensus document from the American Academy of Ophthalmology states that, 'the current preferred (...) for geographic atrophy is limited and consists mainly of counselling, smoking cessation, visual rehabilitation, and nutritional supplements to reduce the risk of progression in those expected to benefit. Treatments for neovascular age-related macular degeneration (AMD): Anti-angiogenic therapies: Vascular endothelial growth factor (VEGF) is a pro-angiogenic growth factor that also stimulates vascular permeability and has a major role in the pathology of neovascular AMD. Drug inhibition of VEGF has become

2016 NICE Clinical Knowledge Summaries

613. Sprains and strains

criteria Audit criteria No audit criteria were found during the review of this topic. QOF indicators QOF indicators No QOF indicators were found during the review of this topic. QIPP - Options for local implementation QIPP - options for local implementation Non-steroidal anti-inflammatory drugs (NSAIDs) Review the appropriateness of NSAID prescribing widely and on a routine basis, especially in people who are at higher risk of both gastrointestinal and cardiovascular morbidity and mortality (...) . CKS has not recommended referral of all muscle strains, because conservative management will result in a good outcome in most cases [ ]. However, the expert opinion of previous reviewers of this CKS topic is that appropriate rehabilitation reduces the likelihood of a further strain and/or residual symptoms, so referral to physiotherapy may be justified. Prevention of further strains and sprains What should I advise on preventing further strains and sprains? Advise that the person should: Take care

2016 NICE Clinical Knowledge Summaries

614. Greater trochanteric pain syndrome (trochanteric bursitis)

, and key randomized controlled trials published since the last revision of this topic. Minor changes to the recommendations on management of greater trochanteric pain syndrome have been made. Previous changes Previous changes July 2013 — minor update. Update to the text to reflect new recommendations by the MHRA regarding diclofenac Diclofenac: new contraindications and warnings after a Europe-wide review of cardiovascular safety, 2013, Medicines and Healthcare products Regulatory Agency . February (...) of General Practice. 57 ( 541 ), 655 - 661 . [ ] Mallow, M. and Nazarian, L.N. ( 2014 ) Greater trochanteric pain syndrome diagnosis and treatment. Physical medicine and rehabilitation clinics of North America. May 2012, 25 ( 2 ), 279 - 289 . [ ] Novatnack, E.S., Protzman, N.M. and Weiss, C.B. ( 2015 ) Primary septic greater trochanteric bursitis. Journal of Global Infectious Diseases. April-June 7 ( 2 ), 93 - 94 . Diane Reid ( 2015 ) The management of greater trochanteric pain syndrome: a systematic

2016 NICE Clinical Knowledge Summaries

615. Pre-patellar bursitis

drugs (NSAIDs) Review the appropriateness of NSAID prescribing widely and on a routine basis, especially in people who are at higher risk of both gastrointestinal (GI) and cardiovascular (CV) morbidity and mortality (e.g. older patients). If initiating an NSAID is obligatory, use ibuprofen (1200 mg per day or less) or naproxen (1000 mg per day or less). Use the lowest effective dose and the shortest duration of treatment necessary to control symptoms. Review patients currently prescribed NSAIDs (...) . The Physican and Sportsmedicine. 28 ( 3 ), 40 - 52 . [ ] MHRA ( 2015 ) Guidance on cox-2 selective inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular safety. MHRA. . [ ] NICE ( 2014 ) Osteoarthritis. Care and management in adults (NICE guideline). Clinical guideline 177. National Institute for Health and Care Excellence. . [ ] NICE ( 2016 ) Medicines optimisation: key therapeutic topics. National Institute for Health and Care Excellence. . Reid CR, Bush PM, Cummings NH, McMullin

2016 NICE Clinical Knowledge Summaries

616. Psychosis and schizophrenia

, are conditions in which psychosis occurs for a significant period of time. They may also be associated with negative symptoms (for example emotional blunting, reduced speech, loss of motivation, self neglect, and social withdrawal). With treatment, psychotic symptoms may resolve fully, recur intermittently with periods of remission between, or persist. Complications include: An increased risk of premature death due to an increased risk of suicide, cardiovascular disease, and type 2 diabetes. Difficulties (...) . Ensure optimal control of psychotic symptoms by: Referring all people at risk of developing a psychotic disorder for specialist assessment and management. Referring all people with suspected psychosis or schizophrenia for specialist assessment and management. Referring all people experiencing a relapse of psychosis or schizophrenia for specialist assessment and management. Manage raised cardiovascular disease risk in people with psychosis through: Annual assessment of cardiovascular disease risk

2016 NICE Clinical Knowledge Summaries

617. Hepatitis A

if they are severely unwell. If admission is not needed: Providing symptomatic supportive care for pain, nausea, or itch if needed. Notifying the local Health Protection Unit promptly — if an outbreak is suspected, or the person is a food handler, notify immediately. Providing information and advice about hepatitis A, including the need to avoid alcohol during the acute illness. Offering referral to a genito-urinary medicine clinic or drug rehabilitation centre, if appropriate. Monitoring liver function tests (...) No audit criteria were found during the review of this topic. QOF indicators QOF indicators No QOF indicators were found during the review of this topic. QIPP - Options for local implementation QIPP - Options for local implementation Non-steroidal anti-inflammatory drugs (NSAIDs) Review the appropriateness of NSAID prescribing widely and on a routine basis, especially in people who are at higher risk of both gastrointestinal (GI) and cardiovascular (CV) morbidity and mortality (e.g. older patients

2016 NICE Clinical Knowledge Summaries

618. Management of cancer pain

Myelographyand lumbar puncture Thoracocentesis Surgery, Chemotherapy, Hormonal therapy, Target therapy Osteonecrosis of the jaw Radiation therapy Steroids can cause pain due to: skin lesions, peripheral neuropathy, mucositis aseptic head femoral necrosis, infections Cardiovascular, Pulmonary Diabetic neuropathy, Vasomotor headache, Fibromyalgia, The comorbidity-related pain may be worsened by anticancer treatments and /or worse cancer-related pain Postherpetic neuralgia Acute thrombosis pain Follow up (...) . Most cancer patients can attain satisfactory relief of pain through an approach that incorporates primary antitumor treatments, systemic analgesic therapy and other noninvasive techniques such as psychological or rehabilitative interventions. treatmentofmildpain Nonopioid analgesics such as acetaminophen/paracetamol or an NSAID are indicated for the treatment of mild pain. NSAIDs are superior to placebo in controlling cancer pain in single dose studies. Paracetamol and NSAIDS are universally

2012 European Society for Medical Oncology

619. Plantar fasciitis

criteria Audit criteria No audit criteria were found during the review of this topic. QOF indicators QOF indicators No QOF indicators were found during the review of this topic. QIPP - Options for local implementation QIPP - Options for local implementation Non-steroidal anti-inflammatory drugs (NSAIDs) Review the appropriateness of NSAID prescribing widely and on a routine basis, especially in people who are at higher risk of both gastrointestinal (GI) and cardiovascular (CV) morbidity and mortality (...) . [ ] Foye,P.M. ( 2013 ) Physical medicine and rehabilitation for plantar fasciitis. eMedicine. Medscape. . [ ] Goff,J.D. and Crawford,R. ( 2011 ) Diagnosis and treatment of plantar fasciitis. American Family Physician. 84 ( 6 ), 676 - 682 . [ ] Hawke,F., Burns,J., Radford,J.A. and du Toit,V. ( 2008 ) Custom-made foot orthoses for the treatment of foot pain (Cochrane Review). The Cochrane Library. John Wiley & Sons, Ltd . [ ] Hyland,M.R., Webber-Gaffney,A., Cohen,L. and Lichtman,P.T. ( 2006 ) Randomized

2015 NICE Clinical Knowledge Summaries

620. Depression

of adaptive mechanisms to stressors. Chronic comorbidities such as diabetes, chronic obstructive pulmonary disease, cardiovascular disease and especially people with chronic pain syndromes. A past head injury, including hypopituitarism following trauma [ ; ]. People at high risk of depression Who is at high risk of depression? People who are at high-risk of depression include anyone with [ ; ]: A history of depression, suicide attempt, or any form of abuse (sexual, physical, or substance). Significant

2015 NICE Clinical Knowledge Summaries

Guidelines

Guidelines – filter by country